Phase III DARE-19 RCT of dapagliflozin to treat patients hospitalised with COVID-19 fails primary endpoint

Primary analysis reported the trial did not achieve statistical significance for the primary endpoints of preventing organ dysfunction and all-cause mortality, or recovery at 30 days in 1,250 pts with underlying hypertension, CVD, heart failure, diabetes or chronic kidney disease

Source:

AstraZeneca Plc.